Heavy chain only antibodies: A new paradigm in personalized HER2+ breast cancer therapy

Seyed Moghimi; Fatemeh Rahbarizadeh; Davoud Ahmadvand; Ladan Parhamifar

doi:10.5681/bi.2013.009

Heavy chain only antibodies: A new paradigm in personalized HER2+ breast cancer therapy

Seyed Moghimi, Fatemeh Rahbarizadeh, Davoud Ahmadvand, Ladan Parhamifar

Research output: Contribution to journal › Editorial › peer-review

17 Scopus citations

Abstract

Unlike conventional antibodies, heavy chain only antibodies derived from camel contain a single variable domain (VHH) and two constant domains (C_H2 and C_H3). Cloned and isolated VHHs possess unique properties that enable them to excel conventional therapeutic antibodies and their smaller antigen-binding fragments in cancer targeting and therapy. VHHs express low immunogenicity, are highly robust and easy to manufacture and have the ability to recognize hidden or uncommon epitopes. We highlight the utility of VHH in design of new molecular, multifunctional particulate and immune cell-based systems for combating HER2+ breast cancer.

Original language	English (US)
Pages (from-to)	1-4
Number of pages	4
Journal	BioImpacts
Volume	3
Issue number	1
DOIs	https://doi.org/10.5681/bi.2013.009
State	Published - Mar 26 2013

Keywords

Chimeric antigen receptors
Heavy chain only antibodies
HER2
Nanotechnology
Single variable domain

ASJC Scopus subject areas

General Medicine
Pharmaceutical Science
General Biochemistry, Genetics and Molecular Biology

Access to Document

10.5681/bi.2013.009

Cite this

@article{0cbb91734c784b6ba3dde5b411204083,

title = "Heavy chain only antibodies: A new paradigm in personalized HER2+ breast cancer therapy",

abstract = "Unlike conventional antibodies, heavy chain only antibodies derived from camel contain a single variable domain (VHH) and two constant domains (CH2 and CH3). Cloned and isolated VHHs possess unique properties that enable them to excel conventional therapeutic antibodies and their smaller antigen-binding fragments in cancer targeting and therapy. VHHs express low immunogenicity, are highly robust and easy to manufacture and have the ability to recognize hidden or uncommon epitopes. We highlight the utility of VHH in design of new molecular, multifunctional particulate and immune cell-based systems for combating HER2+ breast cancer.",

keywords = "Chimeric antigen receptors, Heavy chain only antibodies, HER2, Nanotechnology, Single variable domain",

author = "Seyed Moghimi and Fatemeh Rahbarizadeh and Davoud Ahmadvand and Ladan Parhamifar",

year = "2013",

month = mar,

day = "26",

doi = "10.5681/bi.2013.009",

language = "English (US)",

volume = "3",

pages = "1--4",

journal = "BioImpacts",

issn = "2228-5652",

publisher = "Tabriz University of Medical Sciences",

number = "1",

}

TY - JOUR

T1 - Heavy chain only antibodies

T2 - A new paradigm in personalized HER2+ breast cancer therapy

AU - Moghimi, Seyed

AU - Rahbarizadeh, Fatemeh

AU - Ahmadvand, Davoud

AU - Parhamifar, Ladan

PY - 2013/3/26

Y1 - 2013/3/26

N2 - Unlike conventional antibodies, heavy chain only antibodies derived from camel contain a single variable domain (VHH) and two constant domains (CH2 and CH3). Cloned and isolated VHHs possess unique properties that enable them to excel conventional therapeutic antibodies and their smaller antigen-binding fragments in cancer targeting and therapy. VHHs express low immunogenicity, are highly robust and easy to manufacture and have the ability to recognize hidden or uncommon epitopes. We highlight the utility of VHH in design of new molecular, multifunctional particulate and immune cell-based systems for combating HER2+ breast cancer.

AB - Unlike conventional antibodies, heavy chain only antibodies derived from camel contain a single variable domain (VHH) and two constant domains (CH2 and CH3). Cloned and isolated VHHs possess unique properties that enable them to excel conventional therapeutic antibodies and their smaller antigen-binding fragments in cancer targeting and therapy. VHHs express low immunogenicity, are highly robust and easy to manufacture and have the ability to recognize hidden or uncommon epitopes. We highlight the utility of VHH in design of new molecular, multifunctional particulate and immune cell-based systems for combating HER2+ breast cancer.

KW - Chimeric antigen receptors

KW - Heavy chain only antibodies

KW - HER2

KW - Nanotechnology

KW - Single variable domain

UR - https://www.scopus.com/pages/publications/84879192201

UR - https://www.scopus.com/inward/citedby.url?scp=84879192201&partnerID=8YFLogxK

U2 - 10.5681/bi.2013.009

DO - 10.5681/bi.2013.009

M3 - Editorial

C2 - 23678463

AN - SCOPUS:84879192201

SN - 2228-5652

VL - 3

SP - 1

EP - 4

JO - BioImpacts

JF - BioImpacts

IS - 1

ER -

Heavy chain only antibodies: A new paradigm in personalized HER2+ breast cancer therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this